CD19 and non-Hodgkin lymphoma: Polyfunctional CAR T cell populations, capable of co-expression of more than one cytokine by the same T cell, were associated with greater clinical responses in a clinical trial of CD19 CAR in non-Hodgkin’s lymphoma (45).